Organization | University of Erlangen-Nuremberg

University of Erlangen-Nuremberg Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Founded: Bayreuth Germany (1742)

Organization Overview

First Clinical Trial

2001

NCT00520026

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Alternative names

Assistant Medical Director of the Dept. of Radiooncology | Clinical Research Center, Department of Nephrology and Hypertension, University of Erlangen-Nuremberg | Dean University Hospital Erlangen | Department of Anesthesiology, University Hospital Erlangen | Department of Anesthesiology, University Hospital Erlangen, Germany | Department of Gynecology and Obstetrics, Erlangen University Hospital | Department of Medicine 1 - Gastroenterology, Pneumology and Endocrinology, University Clinic Erlangen, Germany | Department of Medicine 4, University of Erlangen-Nuernberg | Department of Nephrology and Hypertension, University of Erlangen-Nuremberg | Department of Radiotherapy University hospital of Erlangen | Dept. of Pediatric Nephrology, University Hospital Erlangen, Germany | Dept. of Radiation Therapy, University Hospital Erlangen | Dept. of Radiation Therapy, University of Erlangen, Germany | Dermatologische Klinik MIT Poliklinik-Universitaetsklinikum Erlangen | Friedrich-Alexander-Universität Erlangen-Nürnberg | Friedrich-Alexander-Universität Erlange-Nürnberg | Friedrich-Alexander University Erlangen-Nürnberg | Institute for Biomedicine of Aging | Institute for Pathology, Klinikum Bayreuth | Institute of Medical Physics, FAU Erlangen-Nürnberg, Germany | Institute of Medical Physics, Friedrich-Alexander University of Erlangen-Nürnberg | Institute of Medical Physics, University of Erlangen-Nürnberg, Germany | Medizinische Klinik I, University Hospital Erlangen | Microbiology Institute Clinical Microbiology Immunology and Hygiene University Clinic of Erlangen Germany | Pharmacy of the University Hospital Erlangen | Universitaet Erlangen | Universitaetsklinikum Erlangen | Universitätsklinikum Erlangen | Universitätsklinikum Erlangen, Strahlenklinik | University Clinic Erlangen, Clinical Trial Unit, Department of Internal Medicine 3, Rheumatology & Immunology | University Clinic Erlangen, Department of Internal Medicine 3, Rheumatology & Immunology | University clinic Erlangen-Nuernberg | University Erlangen-Nuremberg | University Erlangen Nuremberg Medical School | University Erlangen-Nürnberg | University Erlangen-Nürnberg Erlangen, Germany | University Hospital Erlangen | University Hospital Erlangen, Department of Internal Medicine 3, Rheumatology and Clinical Immunology | University Hospital Erlangen Germany | University Hospital of Erlangen, Germany | University of Erlangen, Germany | University of Erlangen-Nuremberg, Department of Internal Medicine 3, Rheumatology & Immunology | University of Erlangen-Nuremberg, Medical Department 3 | University of Erlangen-Nurnberg | University of Erlangen-Nürnberg | University of Erlangen-Nürnberg, Department of Biology | University of Erlangen-Nürnberg Medical School | University of Erlangen-Nürnberg Medical School, Department of Neurology, Germany | University of Erlangen, Vascular Surgery

University of Erlangen-Nuremberg Report issue

Drugs in Phase 4 Trials (23)

Drugs in Phase 3 Trials (64)

Drugs in Phase 2 Trials (37)

Drugs in Phase 1 Trials (4)

Drugs in Other Trials (20)

Experimental Indications (Clinical Trials, Phases 1-4)

Overview